Bayer stock trades on earnings and pipeline milestones

Bayer stock stays tied to earnings, guidance, and pipeline execution as investors watch the latest reported figures and market context.

Bayer stock (DE000BAY0017) remains a numbers story for investors, with the latest verified company context and market data shaping how the shares are read on 18 July 2026.

Reported figures matter

Bayer reported annual revenue of EUR 47.6 billion in 2024, while EBITDA before special items came in at EUR 10.1 billion and core earnings per share were EUR 5.05 in the same year, according to the companys latest investor materials on its IR site. Those figures give the stock a concrete reference point for valuation and expectations.

The same reporting framework showed net income at EUR 2.6 billion in 2024, compared with a loss in 2023, so the comparison is explicit and important for sentiment. That kind of year-on-year swing often matters more to the market than the headline revenue line.

Revenue and profit set the tone

The 2024 revenue base of EUR 47.6 billion and EBITDA before special items of EUR 10.1 billion together frame the operating leverage investors are watching. Core EPS of EUR 5.05 adds a third hard metric, and the combination gives the stock a clear earnings anchor.

For a company the size of Bayer, these numbers are only part of the story because guidance, litigation costs, and segment performance can shift how earnings are translated into equity value. The market tends to focus on whether profit conversion keeps pace with sales.

Guidance and litigation frame

For 2024, Bayer also pointed to EBITDA before special items of EUR 10.1 billion and core EPS of EUR 5.05, which makes the guidance debate more concrete than a simple sales discussion. Investors usually read those two measures together because they reflect both operating quality and capital discipline.

The legal overhang remains central to the stock narrative because it affects cash generation, balance-sheet flexibility, and the discount the market is willing to apply. That makes the share reaction more sensitive to reported progress than to broad sector headlines.

Crop science stays central

Crop Science remains one of the most important product groups for Bayer, and the segment mix is still relevant because farm economics feed directly into sales and margin trends. That is where changes in demand, pricing, and weather-linked volumes tend to show up first.

The product side also matters because it connects the companys reported revenue base to recurring operating momentum. For Bayer, the product discussion is therefore not a side note but a core part of how the stock is assessed.

Price context for the stock

Bayer shares are best read against the companys latest reported earnings base and the ongoing litigation and segment backdrop, rather than against a single-day narrative. The most durable reference points are the 2024 revenue of EUR 47.6 billion, EBITDA before special items of EUR 10.1 billion, and core EPS of EUR 5.05.

Those metrics define the current investment frame even without a fresh event attached to the stock on this call. In that sense, the shares remain a balance between reported earnings power and the unresolved legal burden.

Bayer stock facts

• Company: Bayer AG
• ISIN: DE000BAY0017
• Ticker: XETRA: BAYN
• Trading venue: Xetra
• Sector / Industry: Health Care / Pharmaceuticals, Biotechnology and Life Sciences
• Index membership: DAX